A new kind of injectable biotech treatment for severe asthma from AstraZeneca and Amgen promises to help a much broader range of patients than existing medicines such as GlaxoSmithKline’s Nucala.
Verastem, Inc.’s experimental blood cancer drug hit its endpoints in a Phase III trial and the news sent shares of company stock up more than 30 percent.
Merck is complementing the company’s immuno-oncology platform and lead PD-1 inhibitor Keytruda with the newly acquired pipeline of a three-year-old German startup.
Drug maker Servier and the French drug regulator will face trial over weight-loss pill Mediator, believed to have caused at least 500 deaths in one of France’s worst health scandals, the prosecutor’s office said.
Patients taking Roche’s targeted lung cancer drug Alecensa have a far lower risk of their disease spreading in the brain than those on Pfizer’s Xalkori, new clinical trial data show.
(Reuters) – Novo Nordisk will pay nearly $58.7 million to resolve claims the drugmaker’s sales staff downplayed the importance of U.S. Food and Drug Administration-mandated warnings about the cancer risks of its diabetes medication Victoza. The U.S. Justice Department said Tuesday’s settlement would resolve claims Novo Nordisk supplied its sales representatives with information to […]
GE Healthcare Launches First-Ever Mammography System that Allows Patients to Control their Compression by Remote Control
GE Healthcare announced FDA 510(k) clearance of an industry-first, patient-assisted mammography device that literally puts women in control of their mammograms.
A federal judge in Delaware invalidated patents held by Mallinckrodt Pharmaceuticals on its Inomax respiratory treatment system.
Insmed Inc. said its drug for the treatment of a rare lung disorder met the main goal in a key study, sending its shares soaring in premarket trading.
Medical device maker Teleflex Inc. said on Tuesday it would buy privately held NeoTract Inc. to strengthen its portfolio of urology devices in its second billion-dollar deal in the past nine months.